138 related articles for article (PubMed ID: 37596935)
1. Nirmatrelvir Resistance-de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure-a Case Report.
Zuckerman NS; Bucris E; Keidar-Friedman D; Amsalem M; Brosh-Nissimov T
Clin Infect Dis; 2024 Feb; 78(2):352-355. PubMed ID: 37596935
[TBL] [Abstract][Full Text] [Related]
2. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system.
Zhou Y; Gammeltoft KA; Ryberg LA; Pham LV; Tjørnelund HD; Binderup A; Duarte Hernandez CR; Fernandez-Antunez C; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
Sci Adv; 2022 Dec; 8(51):eadd7197. PubMed ID: 36542720
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report.
Lindahl AL; Ahava MJ; Haukipää M; Kreivi HR; Lipponen A; Kortela E
Infect Dis (Lond); 2023 Aug; 55(8):585-589. PubMed ID: 37334428
[TBL] [Abstract][Full Text] [Related]
4. High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients.
Huygens S; Gharbharan A; Serroukh Y; Snoek B; Franken B; Oude Munnink BB; Van Hagen PM; Bogers S; Geurtsvankessel CH; Rijnders BJA
J Antimicrob Chemother; 2023 Jul; 78(7):1644-1648. PubMed ID: 37248664
[TBL] [Abstract][Full Text] [Related]
5. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
Mikulska M; Sepulcri C; Dentone C; Magne F; Balletto E; Baldi F; Labate L; Russo C; Mirabella M; Magnasco L; Di Grazia C; Ghiggi C; Raiola AM; Giacobbe DR; Vena A; Beltramini S; Bruzzone B; Lemoli RM; Angelucci E; Bassetti M
Clin Infect Dis; 2023 Jul; 77(2):280-286. PubMed ID: 36976301
[TBL] [Abstract][Full Text] [Related]
6. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
[TBL] [Abstract][Full Text] [Related]
7. Association of nirmatrelvir/ritonavir and remdesivir as treatment for SARS-CoV-2 infection in immunocompromised patients with hematologic malignancies. Series of four cases.
Segura Fábrega A; Pérez Catalán I; Gómez Alfaro I; García Muñoz S; Roig Martí C; Rodríguez Lozano N; Folgado Escudero S; Varea Villanueva M; Gascón Buj A; Torres García M; Reig Valero R; Ferrando Piqueres R; Usó Blasco J
Rev Esp Quimioter; 2023 Dec; 36(6):655-657. PubMed ID: 37786958
[TBL] [Abstract][Full Text] [Related]
8. Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients.
Pérez Catalán I; García Muñoz S; Roig Martí C; Gómez Alfaro I; Serrano Picazo L; Torres García M; Reig Valero R; Ferrando Piqueres R; Mateu Campos L; Ramos Rincón JM; Usó Blasco J
Rev Esp Quimioter; 2022 Dec; 35(6):589-591. PubMed ID: 36250675
[No Abstract] [Full Text] [Related]
9. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
Piñana JL; Heras I; Aiello TF; García-Cadenas I; Vazquez L; Lopez-Jimenez J; Chorão P; Aroca C; García-Vidal C; Arroyo I; Soler-Espejo E; López-Corral L; Avendaño-Pita A; Arrufat A; Garcia-Gutierrez V; Arellano E; Hernández-Medina L; González-Santillana C; Morell J; Hernández-Rivas JÁ; Rodriguez-Galvez P; Mico-Cerdá M; Guerreiro M; Campos D; Navarro D; Cedillo Á; Martino R; Solano C;
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896843
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir.
Kiso M; Furusawa Y; Uraki R; Imai M; Yamayoshi S; Kawaoka Y
Nat Commun; 2023 Jul; 14(1):3952. PubMed ID: 37402789
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
Lanzafame M; Gottardi M; Guella L; Collini L; Costa G; Guella A; Vento S
J Chemother; 2023 Nov; 35(7):623-626. PubMed ID: 37102326
[TBL] [Abstract][Full Text] [Related]
12. Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019.
Yamamoto C; Taniguchi M; Furukawa K; Inaba T; Niiyama Y; Ide D; Mizutani S; Kuroda J; Tanino Y; Nishioka K; Watanabe Y; Takayama K; Nakaya T; Nukui Y
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793600
[TBL] [Abstract][Full Text] [Related]
13. Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature.
Marangoni D; Antonello RM; Coppi M; Palazzo M; Nassi L; Streva N; Povolo L; Malentacchi F; Zammarchi L; Rossolini GM; Vannucchi AM; Bartoloni A; Spinicci M
Int J Infect Dis; 2023 Aug; 133():53-56. PubMed ID: 37150351
[TBL] [Abstract][Full Text] [Related]
14. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir.
Gammeltoft KA; Zhou Y; Ryberg LA; Pham LV; Binderup A; Hernandez CRD; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766376
[TBL] [Abstract][Full Text] [Related]
15. Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab.
Gentile I; Foggia M; Silvitelli M; Sardanelli A; Cattaneo L; Viceconte G
Virol J; 2023 Dec; 20(1):301. PubMed ID: 38102675
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report.
Gidari A; Sabbatini S; Schiaroli E; Bastianelli S; Pierucci S; Busti C; Saraca LM; Capogrossi L; Pasticci MB; Francisci D
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515263
[TBL] [Abstract][Full Text] [Related]
17. Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2.
Hirotsu Y; Kobayashi H; Kakizaki Y; Saito A; Tsutsui T; Kawaguchi M; Shimamura S; Hata K; Hanawa S; Toyama J; Miyashita Y; Omata M
Med; 2023 Nov; 4(11):813-824.e4. PubMed ID: 37683636
[TBL] [Abstract][Full Text] [Related]
18. Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.
Aiello TF; Peyrony O; Chumbita M; Monzó P; Lopera C; Puerta-Alcalde P; Magnano L; Fernández-Avilés F; Cuesta G; Tuset M; Mensa J; Esteve J; Marcos MA; Soriano A; Garcia-Vidal C
Influenza Other Respir Viruses; 2024; 18(3):e13264. PubMed ID: 38468434
[TBL] [Abstract][Full Text] [Related]
19. Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir: Selection not induction.
Colson P; Delerce J; Pontarotti P; Devaux C; La Scola B; Fantini J; Raoult D
J Med Virol; 2024 Feb; 96(2):e29462. PubMed ID: 38363015
[TBL] [Abstract][Full Text] [Related]
20. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
Nature; 2023 Jan; 613(7944):558-564. PubMed ID: 36351451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
